Yearly Archives: "2022"

A new patient assistance offering from Janssen
FOR INSURED PATIENTS WHO ARE FACING ACCESS AND AFFORDABILITY CHALLENGES Janssen believes that access and affordability challenges [...]
Cycle Pharmaceuticals to launch TASCENSO ODT® (fingolimod) in US in Q1 2023
Eligible patients will receive full MS patient support program through Cycle Vita™ Boston, Massachusetts and San Jose, California – [...]
Physician Coalition lauds proposed rule mirroring house-passed bill
Physician Coalition Lauds Proposed Rule Mirroring House-Passed Bill to Streamline Prior Authorization in Medicare Advantage [...]
In memoriam Dr. Jack S. Burks
In Memoriam Jack S. Burks, MD Dr. Burks, or Jack as he liked to be known, was a founder of the CMSC.  He was a visionary; a consummate [...]
Listeria outbreak linked to deli meat and cheese
Advisory for People with MS   The Centers for Disease Control and Prevention has posted an alert that some cold deli meats and cheese [...]
In memory of Dr. George Kraft
I have a sad message to share with members of the CMSC and visitors to our website.  Dr. George Kraft, a strong advocate for MS patients [...]
Genentech to present new Ocrevus (ocrelizumab) data in multiple sclerosis & NMOSD research at ECTRIMS
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® (ocrelizumab) data and continued [...]
US FDA – Ocrevus prescribing information to include warnings for Colitis and PML
Labeling updates to Ocrevus (ocrelizumab) injection, for intravenous use for the treatment of multiple sclerosis (MS) will be [...]
2021 MAGNIMS-CMSC-NAIMS MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-up of MS
Clinician's User Manual Summary of 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple [...]
More About MS (2022)
In this program, people living with or affected by MS will have the opportunity to network with one another and to learn from leading MS [...]

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM